12 completed, 8 terminated, 1 unknown. 21 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 12, Terminated 8, Unknown 1 |
| Phase 2 | 9 | Terminated 5, Completed 3, Unknown 1 |
Follow Recombinant Interleukin-2: new trials by email Literature Review of Recombinant Interleukin-2 trials Research Report on Recombinant Interleukin-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation aldesleukin - Kidney Transplantation | Phase 1 / Phase 2 | Terminated | Anil K. Chandraker, MD | 2 | 2015-09-01 | 2021-06-24 |
| Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia decitabine, natural killer cell therapy, aldesleukin - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1 | Completed | Sumithira Vasu | 8 | 2015-04-21 | 2020-03-09 |
| Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma IL-2, GD2Bi-aATC, GM-CSF - Disseminated Neuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Unknown | University of Virginia | 40 | 2014-11-01 | 2019-01-29 |
| Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Fludarabine, Cyclophosphamide, Leukapheresis - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Terminated | Washington University School of Medicine | 89 | 2014-08-11 | 2024-01-17 |
| Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies cyclophosphamide, fludarabine phosphate, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 4 | 2014-07-17 | 2019-02-28 |
| Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma cyclophosphamide, aldesleukin, autologous tumor cell vaccine - Recurrent Melanoma, Stage IV Melanoma | Phase 1 | Completed | Fred Hutchinson Cancer Center | 12 | 2012-03-01 | 2014-04-21 |
| Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 1 | Completed | City of Hope Medical Center | 6 | 2011-03-22 | 2026-10-19 |
| Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma therapeutic autologous lymphocytes, aldesleukin, cyclophosphamide - Stage IV Melanoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 12 | 2010-04-01 | 2011-12-21 |
| Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox - Recurrent Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2009-07-01 | 2022-11-15 |
| Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma ipilimumab, cyclophosphamide, biopsy - Recurrent Melanoma, Stage IV Melanoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 10 | 2009-02-01 | 2017-04-19 |
| Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma therapeutic autologous lymphocytes, aldesleukin, cyclophosphamide - Recurrent Melanoma, Stage IV Melanoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 10 | 2007-09-01 | 2017-02-15 |
| Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma therapeutic autologous lymphocytes, cyclophosphamide, aldesleukin - B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 | Completed | Fred Hutchinson Cancer Center | 12 | 2007-08-01 | 2014-08-06 |
| Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma cyclophosphamide, therapeutic autologous lymphocytes, aldesleukin - Recurrent Melanoma, Stage IV Melanoma | Phase 1 | Completed | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 11 | 2006-12-01 | 2012-03-16 |
| Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma recombinant interleukin-12, aldesleukin - Recurrent Neuroblastoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 40 | 2002-12-01 | 2013-04-09 |
| Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 7 | 2002-09-01 | 2017-02-15 |
| Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides aldesleukin, recombinant interleukin-12, laboratory biomarker analysis - Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 46 | 2002-09-01 | 2013-01-16 |
| Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation therapeutic allogeneic lymphocytes, aldesleukin, peripheral blood stem cell transplantation - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 37 | 2002-09-01 | 2017-03-29 |
| Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma monoclonal antibody Ch14.18, isotretinoin, aldesleukin - Disseminated Neuroblastoma, Recurrent Neuroblastoma | Phase 1 | Completed | National Cancer Institute (NCI) | 6 | 2001-01-01 | 2013-01-16 |
| Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer rituximab, aldesleukin, laboratory biomarker analysis - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2000-12-01 | 2013-06-06 |
| Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors recombinant interleukin-12, aldesleukin, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 25 | 2000-03-01 | 2013-02-01 |
Showing 20 of 21. Sign in to see all of them.
Melanoma (6) · Leukemia, Myeloid, Acute (4) · Congenital Abnormalities (3) · Neuroblastoma (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia, Refractory, with Excess of Blasts (1) · Astrocytoma (1) · Blast Crisis (1) · Brain Neoplasms (1) · Burkitt Lymphoma (1) · Ependymoma (1)
Fred Hutchinson Cancer Center (8) · National Cancer Institute (NCI) (5) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (2) · Anil K. Chandraker, MD (1) · City of Hope Medical Center (1) · Jonsson Comprehensive Cancer Center (1) · Sumithira Vasu (1) · University of Virginia (1) · Washington University School of Medicine (1)
United States (21)
Cassian Yee (3) · Sylvia Lee (2) · Alain Rook (1) · Amanda Cashen, M.D. (1) · Andrew Gilman (1) · Antoni Ribas (1) · Aude Chapuis (1) · Behnam Badie (1) · Brian Till (1) · David Maloney (1) · Gunnar Ragnarsson (1) · Jon Wigginton (1) · Maxim Yankelevich (1) · Merav Bar (1) · Michael Atkins (1)
PMID 22308288, PMID 27269940, PMID 30573690, PMID 33986124, PMID 34797911
K12CA076930 (3), P01CA018029 (2), F32CA200253 (1), P01CA081403 (1), P30CA016042 (1), P30CA022453 (1), R01CA089442 (1), R21CA128283 (1), R21CA137647 (1), U01CA076576 (1)